A B S T R A C T Biological properties of pure natural human "big gastrin" (designated G-34 because it contains 34 amino acid residues) were compared with those of pure natural heptadecapeptide gastrins (G-17) from human and porcine sources. Radioimmunoassay inhibition curves indicated that G-17 was nearly 1.5 times more potent than G-34 with the antibody used in this study. This difference was confirmed by demonstration of increased immunoreactivity generated when G-34 was converted to G-17 by trypsinization.
INTRODUCTION
Radioimmunoassay systems currently employed for measurement of gastrin all use heptadecapeptide gastrin (G-17)' as the standard, most commonly nonsulfated human gastrin I (HG-17-I), porcine gastrin I (PG-17-I), or sulfated porcine gastrin II (PG-17-II) (1) (2) (3) . Yalow and Berson recently reported that the principal circulating form of gastrin in hypergastrinemic humans was a larger molecule which they named "big gastrin" (4) . This observation has been extended by them (5, 6) and has been confirmed by others (7, 8) .
Gregory and Tracy extracted human big gastrin from gastrin-secreting tumors of the Zollinger-Ellison variety and have showed that it contains 34 amino acid residues (9) . Both sulfated and nonsulfated forms were identified. Throughout the remainder of this paper HG-34-I and HG-34-II will be used to designate the nonsulfated and sulfated forms of human big gastrin.
The purpose of the present investigation was to compare G-34 and G-17 preparations in regard to acid stimulation, rates of elimination from the circulation, and the relation between acid secretion rates and change in serum immunoreactive gastrin.
METHODS
Gastrins. All gastrin preparations were generous gifts from Professor R. A. Gregory and Dr. Hilda Tracy, University of Liverpool. Porcine gastrins, PG-17-I and PG-17-II, were obtained from extracts of hog antral mucosa (10) . Natural human gastrins, HG-34-I, HG-34-II, and HG-17-I were obtained from gastrin-secreting tumors of the Zollinger-Ellison variety. Each peptide was purified by AE-cellulose chromatography and column electrophoresis (11) . The purity of each of the gastrin preparations was proved by homogeneity in these systems and by quantitative amino acid analysis.
Animals. Four mongrel dogs weighing between 20 and 26 kg were prepared with gastric fistulas drained by Thomas cannulas (12) and Heidenhain pouches drained by Gregory cannulas (13) . Experiments were performed at least 3 mo after operation. The dogs were deprived of food but not water for 18 h before each test. Experiments were performed no more than twice per week.
The maximal acid secretory capacity of each pouch was determined by stimulation with pentagastrin (Ayerst Laboratories, New York) at doses of 8 and 16 ,tg/kg-h. Each dose was given on separate days and each dog was studied twice. The highest rate of acid secretion obtained for three consecutive 10 -min periods was taken as the maximal pentagastrin response. Acid secretory rates were determined as previously described (14) by titration to pH 7 on an autotitrator (Autoburette, Radiometer Co., Copenhagen). All other acid secretion rates were expressed as percent maximal pentagastrin-stimulated secretion to minimize variations due to differences in the sizes of the pouches.
Gastrin solutions were prepared in 0.05 M NH4HCO3. Absorbance at 280 nm was measured in a Zeiss PMQ-II spectrophotometer (Carl Zeiss, Inc., New York) and gastrin concentrations were calculated from the molar extinction coefficients. G-17 and G-34 have identical C-terminal heptadecapeptide composition and the N-terminal heptadecapeptide portion of G-34 contains no tryptophan or tyrosine (R. A. Gregory, personal communication). Therefore the extinction coefficients for G-17 and G-34 are identical. Sulfation of tyrosine decreases the extinction coefficient of tyrosine from 1,507 to less than 1 (15) Serum gastrin measurements were done by radioimmunoassay as previously described (3). The antibody used for these assays was no. 2604, donated by Dr. Jens Rehfeld, Copenhagen (18) , and was used at a final dilution of 1:120,000. Natural HG-17-I was labeled with 'I and repurified by starch gel electrophoresis (2) . Approximately 1,600 cpm of labeled gastrin were used in each 2-ml incubation, giving a concentration of labeled gastrin less than 1 pg/ml in the incubation. Gastrin solutions used for infusion were saved and used for radioimmunoassay standards and for determination of relative immunopotency. Separation was done with ion-exchange resin IRP 58M (2) .
Immunoreactivity of G-17 and G-34. Preliminary experiments were done to determine the immunochemical potency of HG-34-I and HG-34-II compared with the corresponding human and porcine heptadecapeptides. Table II . Serum gastrin concentrations 30-60 min after cessation of infusion of the various gastrins did not differ significantly from basal values obtained before infusion.
Serum immunoreactive gastrin during and after gastrin infusions. For each molar dose, G-34 preparations produced higher blood levels of gastrin than G-17 preparations. Results of infusion with HG-34-II and PG-17-II are shown in Fig. 4 . Increment in serum gastrin was linearly related to dose of gastrin (Table III) Table IV . In these dogs the half times of the G-17 preparations were between 2.7 and 3.9 min and for the G-34 preparations between 14.7 and 16.8 min. The mean ratio of half times of G-34 and G-17 was 4.9 which agrees satisfactorily with the mean ratio of slopes of regression of serum gastrin increment on dose, 5.8. These two ratios are independent estimates of relative removal rates. Space of distribution was similar for all preparations, ranging from 22 to 28% body weight. Clearance rate for G-17 was six times greater than for G-34. Acid secretion vs. infusion rate and change in serum gastrin. Complete results of all infusion studies in individual dogs are given in Table V . For equimolar rates of infusion, the acid secretory rates produced by G-34 were modestly greater than those produced by (Fig. 6 ).
The comparability of HG-17-I and of PG-17-I is shown in Fig. 7 . There was no significant difference in potency as stimulants of acid secretion, and as already Rehfeld has identified gastrin immunoreactivity which elutes between big-big gastrin and G-34 (7). The biological activity of this material, known as "component I" also remains to be determined. A smaller molecular form of gastrin, "minigastrin" (G-13, the C-terminal tridecapeptide of G-17), also has been found to comprise a small fraction of serum immunoreactive gastrin (7) .
The exogenous potency of minigastrin in the dog is approximately half that of G-17 and the half-life is similar to that of G-17 (26) .
The measured gastrin concentration in the circulation may vary according to the immunochemical specificities of the antibodies employed in radioimmunoassay. Most assay systems have been defined by the inhibition curve produced with a G-17 standard and have not considered possible immunochemical differences between G-17 and G-34 or other circulating forms of gastrin. Yalow (6) and Rehfeld (18) have reported similar inhibition with G-17 and G-34 in their systems. Such antibodies should be useful in determination of total immunoreactive serum gastrin regardless of molecular species but may provide misleading estimates of acid-stimulating action if there is a predominance of a single form. Antibodies which detect a single molecular size of gastrin and have minimal reactivity with other sizes might be used in combination to define the molecular pattern of gastrin in the serum. Antibody 1295 appears to be highly specific for G-17 (26) , but antibodies specific for G- 34 have not yet been reported. Hansky (27) reported an antibody which differentiates between sulfated and nonsulfated gastrins. We have produced antibodies with similar specificities (26) . In addition, some antibodies, especially those produced by immunization of guinea pigs with crude gastrin distinguish amino acid substitutions in the G-17 molecule among species (26) . With such antibodies pure gastrin from the appropriate species must be used as the standard to obtain accurate estimates of gastrin concentration.
Until antibodies of known specificities are available which clearly distinguish the different forms of gastrin, the best separation method available is fractionation by size, charge, or both (4, 8) followed by assay of each fraction with a broadly reactive antibody. Such fractionation studies may permit some as yet unrecognized distinctions between normal subjects and those with gastric acid hypersecretion and/or peptic ulcer disease. For example, if it were found that some persons have a predominance of G-17 rather than big-big gastrin in their fasting serum, this could account for basal acid hypersecretion with normal total serum gastrin concentrations.
